Merials

Merials was a global animal health company, formed in 1997 as a joint venture between Merck (known as MSD outside the United States and Canada) and Sanofi-Synthélabo. The company's focus was on the research, development, manufacturing, and marketing of veterinary pharmaceuticals and vaccines for both companion animals and livestock. Merials' product portfolio included a wide range of solutions addressing common health concerns in animals, such as parasiticides, vaccines for infectious diseases, and treatments for chronic conditions.

Throughout its existence, Merials was recognized for its commitment to innovation in animal health. The company invested significantly in research and development, aiming to create new and improved products to enhance animal welfare and support the agricultural industry. Key therapeutic areas included flea and tick control, heartworm prevention, and vaccines against rabies and other prevalent diseases. Merials operated on a global scale, with a presence in numerous countries and a distribution network that reached veterinarians and animal owners worldwide.

In 2017, Merials was acquired by Boehringer Ingelheim, another leading animal health company. This acquisition resulted in the integration of Merials' operations and product lines into Boehringer Ingelheim's existing business, creating one of the largest animal health companies globally. The legacy of Merials continues through the products and scientific advancements that have become part of Boehringer Ingelheim's offerings.